menu
    • menu
    [{"orgOrder":0,"company":"Molecure","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"POLAND","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"OATD-01","moa":"Chitinase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Molecure","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Molecure \/ Galapagos","highestDevelopmentStatusID":"4","companyTruncated":"Molecure \/ Galapagos"},{"orgOrder":0,"company":"Molecure","sponsor":"Galapagos","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"POLAND","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"OATD-01","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Molecure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Molecure \/ Galapagos","highestDevelopmentStatusID":"8","companyTruncated":"Molecure \/ Galapagos"},{"orgOrder":0,"company":"Molecure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"POLAND","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"OATD-01","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Molecure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Molecure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Molecure \/ Not Applicable"},{"orgOrder":0,"company":"Molecure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"POLAND","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"OATD-01","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Molecure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Molecure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Molecure \/ Not Applicable"},{"orgOrder":0,"company":"Molecure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"POLAND","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"OATD-01","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Molecure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Molecure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Molecure \/ Not Applicable"},{"orgOrder":0,"company":"Molecure","sponsor":"Avicenna Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRAN","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Molecure","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Molecure \/ Molecure","highestDevelopmentStatusID":"2","companyTruncated":"Molecure \/ Molecure"},{"orgOrder":0,"company":"Molecure","sponsor":"Ocean Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"POLAND","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"OAT-3912","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Molecure","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Molecure \/ Ocean Biomedical","highestDevelopmentStatusID":"4","companyTruncated":"Molecure \/ Ocean Biomedical"}]

    Find Clinical Drug Pipeline Developments & Deals by Molecure

    Menu

    Molecure

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Molecure

                            Poland arrow
                            PharmaVenue
                            Not Confirmed

                            Molecure

                            Poland arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OAT-3912

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Ocean Biomedical

                            Deal Size : $32.6 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Ocean Biomedical Pens $32M Pact for Polish YKL-40 Inhibitors

                            Details : Under the agreement, Ocean Biomedical gains the exclusive rights to further research, develop, manufacture and commercialize Molecure’s OAT-3912 and other selective YKL-40 inhibitors worldwide.

                            Brand Name : OAT-3912

                            Molecule Type : Large molecule

                            Upfront Cash : $0.6 million

                            October 15, 2024

                            Lead Product(s) : OAT-3912

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Ocean Biomedical

                            Deal Size : $32.6 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Molecure

                            Poland arrow
                            PharmaVenue
                            Not Confirmed

                            Molecure

                            Poland arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : Avicenna Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Avicenna Biosciences & Molecure S.A. Sign Collaboration for Small Molecule Drug Discovery

                            Details : Under the terms of the agreement, Avicenna will design algorithms to identify NCE that inhibit USP7, an attractive target in cancer that regulates the stability of crucial proteins involved in tumors.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 31, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : Avicenna Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Molecure

                            Poland arrow
                            PharmaVenue
                            Not Confirmed

                            Molecure

                            Poland arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OATD-01

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Molecure Receives Approval for Phase II Trial of OATD-01 for Pulmonary Sarcoidosis

                            Details : OATD-01 is an oral, once-daily, first-in-class, and highly selective CHIT1 inhibitor for use in the treatment of pulmonary sarcoidosis. The company has recieved approval to initiate P2 trial.

                            Brand Name : OATD-01

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 21, 2024

                            Lead Product(s) : OATD-01

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Molecure

                            Poland arrow
                            PharmaVenue
                            Not Confirmed

                            Molecure

                            Poland arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OATD-01

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            First UK Patient Dosed in OATD-01 Phase 2 KITE Study for Pulmonary Sarcoidosis

                            Details : OATD-01 is an oral, small molecule inhibitor of chitinase-1 (CHIT1), which is being evaluated for the treatment of patients with acute pulmonary sarcoidosis.

                            Brand Name : OATD-01

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 22, 2024

                            Lead Product(s) : OATD-01

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Molecure

                            Poland arrow
                            PharmaVenue
                            Not Confirmed

                            Molecure

                            Poland arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OATD-01

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            The U.S. Food and Drug Administration Gives the Green Light to Molecure's Flagship Program Phase II Clinical T...

                            Details : OATD-01, is an oral, once-daily, first-in-class highly selective CHIT1 inhibitor for the treatment of pulmonary sarcoidosis. The inhibition of CHIT1 by OATD‑01 has been shown to reduce inflammation & fibrosis.

                            Brand Name : OATD-01

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 24, 2023

                            Lead Product(s) : OATD-01

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Molecure

                            Poland arrow
                            PharmaVenue
                            Not Confirmed

                            Molecure

                            Poland arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OATD-01

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Galapagos

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Molecure Files an Investigational New Drug (IND) application for lead clinical candidate OATD-01 with U.S. FDA...

                            Details : OATD-01, is an oral, once-daily, first-in-class highly selective CHIT1 inhibitor for the treatment of pulmonary sarcoidosis. The inhibition of CHIT1 by OATD‑01 has been shown to reduce inflammation & fibrosis.

                            Brand Name : OATD-01

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 23, 2023

                            Lead Product(s) : OATD-01

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Galapagos

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Molecure

                            Poland arrow
                            PharmaVenue
                            Not Confirmed

                            Molecure

                            Poland arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OATD-01

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Preclinical

                            Sponsor : Galapagos

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Molecure To Regain Worldwide Rights to Dual Chitinase Inhibitor OATD-01

                            Details : Molecure has regained (at no cost) the full and exclusive rights to the results of all research, pre-clinical and clinical development performed by Galapagos with OATD-01 over the course of the last 18 months.

                            Brand Name : OATD-01

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 23, 2022

                            Lead Product(s) : OATD-01

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Galapagos

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth